NCT06076772Not yet recruiting
Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients
Source: ClinicalTrials.gov · Last updated 11 Oct 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Aim of the study to assess the neutropenia induced by Palbociclib in patient receiving Palbociclib in combination with hormonal treatment as first-line therapy in metastatic hormone receptor- positive HER2 negative breast cancer. To evaluate the risk factors for occurrence of neutropenia and treatment outcome as 2 years PFS and OS.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 54 (estimated)
- First submitted
- 18 Sept 2023
- Start date
- Nov 2023
- Primary completion date
- Sept 2026
- Lead sponsor
- Assiut University
- NCT number
- NCT06076772
What you commit to
- Study type: Observational
- Planned participants: 54
- From Nov 2023 to the primary completion date, Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patient with co-morbidity
- Pregnant and breast lactating women
Who the study is looking for
- Histological pathological confirmation of primary breast cancer or metastatic disease.
- Hormonal receptor-positive, HER2 negative.
- Metastatic breast cancer at presentation (Den novo) or recurrent.
- Patients did not receive any previous systemic therapy for metastatic disease.
- Performance status (ECOG) 0-2.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Asmaa Imam Ahmed Coordinator of this site? Confirm its status | Al Madīnah | Saudi Arabia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.